Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01327300 · ClinicalTrials.gov registry record · Phase 2
Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)
A Phase 2 study, sponsored by University of Florida.
- Completed
- Registry status
- Phase 2
- Development phase
- 7
- Enrollment target
NCT01327300 is a Phase 2 study that has completed, run by University of Florida. The registered enrollment target is 7 participants.
The verdict
NCT01327300, a Phase 2 study, has completed, sponsored by University of Florida.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this study is to find whether treating patients with diarrhea predominant Irritable Bowel Syndrome (IBS) with an anti-inflammatory drug called Mesalamine will help improve their symptoms of diarrhea, bloating and abdominal pain.
Interventions
- OTHER Placebo
- DRUG Mesalamine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2010-03 |
| Est. Completion | 2012-03 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01327300
The ClinicalTrials.gov registry entry for NCT01327300 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 7 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Florida, which has 1,106 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01327300 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01327300 about?
NCT01327300 is a clinical study titled "Efficacy of Mesalamine in Diarrhea-predominant Irritable Bowel Syndrome (dIBS)". The purpose of this study is to find whether treating patients with diarrhea predominant Irritable Bowel Syndrome (IBS) with an anti-inflammatory drug called Mesalamine will help improve their symptoms of diarrhea, bloating and abdominal pain.
What is the current status of trial NCT01327300?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 7 participants. The study started on 2010-03. Estimated completion is 2012-03.
What interventions are being tested in trial NCT01327300?
The interventions under investigation include: Placebo (OTHER), Mesalamine (DRUG).
Who is sponsoring clinical trial NCT01327300?
This trial is sponsored by University of Florida, which has 1,106 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.